For the cumulative Q3 period of the fiscal year ending June 2026, net sales amounted to JPY 161.710 billion (up 9.7% YoY), operating income was JPY 8.022 billion (up 17.3% YoY), and net income attributable to owners of the parent for the quarter was JPY 5.621 billion (up 15.4% YoY).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"9267","jir_company_name":"Genky DrugStores Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-04-28","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/9267-20260428-02.pdf","jir_short_summary":"For the cumulative Q3 period of the fiscal year ending June 2026, net sales amounted to JPY 161.710 billion (up 9.7% YoY), operating income was JPY 8.022 billion (up 17.3% YoY), and net income attributable to owners of the parent for the quarter was JPY 5.621 billion (up 15.4% YoY).","jir_summary":"### Business Overview\nDuring the cumulative Q3 period of the fiscal year ending June 2026, net sales reached JPY 161.710 billion (up 9.7% YoY), operating income was JPY 8.022 billion (up 17.3% YoY), ordinary income totaled JPY 8.168 billion (up 15.9% YoY), and net income attributable to owners of the parent for the quarter was JPY 5.621 billion (up 15.4% YoY). Despite the impact of new store openings and closures, the company advanced its dominant area strategy and pursued low-cost operations, resulting in increased revenue and profits. By store format, \"R Stores\" recorded JPY 143.438 billion, \"Large Stores\" JPY 18.049 billion, and \"Others\" JPY 0.221 billion. By product category, \"Food\" accounted for JPY 115.127 billion, \"Sundries\" JPY 18.433 billion, \"Cosmetics\" JPY 14.815 billion, \"Pharmaceuticals\" JPY 12.155 billion, and \"Others\" JPY 1.178 billion.\n\n### Financial Position Overview and Earnings Guidance\nTotal assets increased by JPY 15.014 billion compared to the end of the previous consolidated fiscal year to JPY 142.340 billion, and net assets rose by JPY 5.662 billion to JPY 59.090 billion. Total liabilities increased by JPY 9.352 billion to JPY 83.250 billion compared to the end of the previous fiscal year. The equity ratio was 41.4%, remaining nearly flat compared to 41.8% for the same period last year. Shares outstanding totaled 31,031,568, up from the end of the previous term, while treasury stock decreased to 532,069 shares. The consolidated earnings forecast for the full fiscal year ending June 2026 anticipates net sales of JPY 221.2 billion (up 10.2% YoY), operating income of JPY 11.05 billion (up 14.4% YoY), and net income attributable to owners of parent of JPY 7.85 billion (up 11.1% YoY).","jir_financial_highlights":"Net Sales: JPY 161,710 million (Up 9.7% Year-over-Year)\nOperating Income: JPY 8,022 million (Up 17.3% Year-over-Year)\nOrdinary Income: JPY 8,168 million (Up 15.9% Year-over-Year)\nNet Income Attributable to Owners of Parent (Quarter): JPY 5,621 million (Up 15.4% Year-over-Year)\nEarnings Per Share (Quarter): JPY 184.61 (Increased from JPY 160.34 in the same period last year)\nTotal Assets: JPY 142,340 million (Increased by JPY 15,014 million from the end of the previous consolidated fiscal year)\nNet Assets: JPY 59,090 million (Increased by JPY 5,662 million from the end of the previous consolidated fiscal year)\nEquity Ratio: 41.4% (Slight decrease from 41.8% in the same period last year)\nShares Outstanding (Common Stock): 31,031,568 shares (Increased from 30,996,968 shares at the end of the previous term)\nTreasury Stock at Fiscal Year-End: 532,069 shares (Decreased from 601,053 shares at the end of the previous term)","jir_category":"","jir_hashtags":"#GenkyDrugStores, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales: JPY 161,710 million (up 9.7% Year-over-Year)\nOperating Income: JPY 8,022 million (up 17.3% Year-over-Year)\nNet Income Attributable to Owners of Parent (Quarter): JPY 5,621 million (up 15.4% Year-over-Year)","jir_meta_title":"[Genky DrugStores] Q3 Financial Summary for Fiscal Year Ending June 2026 | Net Sales JPY 161.7 Billion (+9.7%)","jir_meta_description":"Genky DrugStores Co., Ltd. Q3 Financial Summary for the fiscal year ending June 2026. Net sales reached JPY 161.7 billion, operating income JPY 8.0 billion, and net income JPY 5.6 billion, achieving year-over-year increases. Full-year forecast also projects profit growth.","jir_og_title":"[Genky DrugStores] Q3 Financial Summary for Fiscal Year Ending June 2026 | Net Sales JPY 161.7 Billion (+9.7%)","jir_og_description":"Q3 financial summary for the fiscal year ending June 2026. Net sales: JPY 161.7 billion, operating income: JPY 8.0 billion, net income: JPY 5.6 billion, achieving year-over-year growth.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Sales Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 Fiscal Year Ending June 2025\\\",\\\"Q3 Fiscal Year Ending June 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[147383,161710],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 Fiscal Year Ending June 2025\\\",\\\"Q3 Fiscal Year Ending June 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[6839,8022],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent (Quarter) Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 Fiscal Year Ending June 2025\\\",\\\"Q3 Fiscal Year Ending June 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[4873,5621],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"equity_ratio_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Equity Ratio Trend (%)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year End June 2025\\\",\\\"Q3 Fiscal Year Ending June 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Equity Ratio\\\",\\\"data\\\":[41.8,41.4],\\\"fill\\\":false,\\\"borderColor\\\":\\\"#76b7b2\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false,\\\"min\\\":40,\\\"max\\\":45}}}}\"}, {\"jir_chart_id\": \"shares_outstanding\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Shares Outstanding Trend (shares)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year End June 2025\\\",\\\"Q3 Fiscal Year Ending June 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Shares Outstanding\\\",\\\"data\\\":[30996968,31031568],\\\"backgroundColor\\\":\\\"#59a14f\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}]","ir_related_company":9174,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-43757","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n